WO2008135674A3 - Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique - Google Patents

Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique Download PDF

Info

Publication number
WO2008135674A3
WO2008135674A3 PCT/FR2008/000416 FR2008000416W WO2008135674A3 WO 2008135674 A3 WO2008135674 A3 WO 2008135674A3 FR 2008000416 W FR2008000416 W FR 2008000416W WO 2008135674 A3 WO2008135674 A3 WO 2008135674A3
Authority
WO
WIPO (PCT)
Prior art keywords
ibuprofen
cyclodextrines
pharmaceutical uses
agent complexes
ternary agent
Prior art date
Application number
PCT/FR2008/000416
Other languages
English (en)
Other versions
WO2008135674A2 (fr
Inventor
Bernard Freiss
Hubert Lochard
Original Assignee
Pf Medicament
Bernard Freiss
Hubert Lochard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament, Bernard Freiss, Hubert Lochard filed Critical Pf Medicament
Priority to EP08787859A priority Critical patent/EP2142187A2/fr
Priority to JP2010500319A priority patent/JP2010522730A/ja
Priority to CA002682250A priority patent/CA2682250A1/fr
Priority to US12/450,391 priority patent/US20100087392A1/en
Publication of WO2008135674A2 publication Critical patent/WO2008135674A2/fr
Publication of WO2008135674A3 publication Critical patent/WO2008135674A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant de l'ibuprofène sous forme d'un complexe ibuprofène/cyclodextrine/lysine ou ibuproféne / cyclodextrine / argimne présentant des propriétés pharmacocinétiques améliorées par rapport à de l'ibuprofène seul tels qu'un Tmax raccourci et un Cmax accru.
PCT/FR2008/000416 2007-03-28 2008-03-26 Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique WO2008135674A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08787859A EP2142187A2 (fr) 2007-03-28 2008-03-26 Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique
JP2010500319A JP2010522730A (ja) 2007-03-28 2008-03-26 イブプロフェン、シクロデキストリンと第３の作用物質の錯体、および薬学におけるその利用方法
CA002682250A CA2682250A1 (fr) 2007-03-28 2008-03-26 Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique
US12/450,391 US20100087392A1 (en) 2007-03-28 2008-03-26 Complexes of ibuprofen, cyclodextrins and ternary agents and the use thereof in pharmaceutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702246 2007-03-28
FR0702246A FR2914187B1 (fr) 2007-03-28 2007-03-28 Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.

Publications (2)

Publication Number Publication Date
WO2008135674A2 WO2008135674A2 (fr) 2008-11-13
WO2008135674A3 true WO2008135674A3 (fr) 2008-12-24

Family

ID=38684513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000416 WO2008135674A2 (fr) 2007-03-28 2008-03-26 Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique

Country Status (6)

Country Link
US (1) US20100087392A1 (fr)
EP (1) EP2142187A2 (fr)
JP (1) JP2010522730A (fr)
CA (1) CA2682250A1 (fr)
FR (1) FR2914187B1 (fr)
WO (1) WO2008135674A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2944280B1 (fr) * 2009-04-09 2012-08-03 Galderma Res & Dev Procede de preparation de complexes moleculaires entre adapalene et des cyclodextrines
FR2944207B1 (fr) * 2009-04-09 2011-05-06 Galderma Res & Dev Compositions comprenant au moins un complexe compose d'un derive d'acide naphtoique et d'au moins une cyclodestrine et leurs utilisations
HUE029953T2 (en) * 2009-04-27 2017-04-28 Laboratorio De Aplicaciones Farm S A Oral ibuprofen lysate suspension
JP5977672B2 (ja) * 2009-04-27 2016-08-24 ラボラトリオ デ アプリカシオネス ファルマコディナミカス，エセ．アー．Ｌａｂｏｒａｔｏｒｉｏ Ｄｅ Ａｐｌｉｃａｃｉｏｎｅｓ Ｆａｒｍａｃｏｄｉｎａｍｉｃａｓ，Ｓ．Ａ． イブプロフェンリシナートの経口投与用の懸濁液
CN105903028B (zh) * 2010-12-31 2020-10-16 东塘实验室有限公司 含有环糊精的细胞水合组合物
JP2014502612A (ja) * 2010-12-31 2014-02-03 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
EP3981380A1 (fr) * 2013-03-12 2022-04-13 Primal Therapies, Inc. Composition antimicrobienne comprenant un agent chélateur et un aminoacide basique
JP2015044850A (ja) * 2014-11-07 2015-03-12 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
KR20220084304A (ko) * 2019-10-21 2022-06-21 이솔레이트 엘티디 초미세 화합물을 포함하는 조성물 및 이의 제조
JP7495340B2 (ja) 2020-12-16 2024-06-04 株式会社ファンケル カルノシン酸含有固体組成物及びカルノシン酸の溶出促進方法
CN114588107B (zh) * 2022-04-06 2023-04-18 河北一品生物医药有限公司 一种布洛芬赖氨酸盐注射液及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346006A1 (fr) * 1988-06-09 1989-12-13 Reckitt And Colman Products Limited Compositions pharmaceutiques contenant des complexes de cyclodextrine et d'ibuprofène
EP1129709A2 (fr) * 2000-03-03 2001-09-05 Laboratorio de Aplicaciones Farmacodinamicas, S.A. Composition pharmaceutique comprenant de l'ibuprofène et procédé pour sa préparation
FR2868315A1 (fr) * 2004-04-01 2005-10-07 Pierre Fabre Medicament Sa Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique
WO2005097201A2 (fr) * 2004-04-01 2005-10-20 Pierre Fabre Medicament Complexes d’inclusions comprenant du piroxicam, une cyclodextrine et l’arginine
FR2876910A1 (fr) * 2004-10-21 2006-04-28 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346006A1 (fr) * 1988-06-09 1989-12-13 Reckitt And Colman Products Limited Compositions pharmaceutiques contenant des complexes de cyclodextrine et d'ibuprofène
EP1129709A2 (fr) * 2000-03-03 2001-09-05 Laboratorio de Aplicaciones Farmacodinamicas, S.A. Composition pharmaceutique comprenant de l'ibuprofène et procédé pour sa préparation
FR2868315A1 (fr) * 2004-04-01 2005-10-07 Pierre Fabre Medicament Sa Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique
WO2005097201A2 (fr) * 2004-04-01 2005-10-20 Pierre Fabre Medicament Complexes d’inclusions comprenant du piroxicam, une cyclodextrine et l’arginine
FR2876910A1 (fr) * 2004-10-21 2006-04-28 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAROENCHAITRAKOOL M ET AL: "Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-beta-cyclodextrin", INTERNATIONAL JOURNAL OF PHARMACEUTICS (KIDLINGTON), vol. 239, no. 1-2, 4 June 2002 (2002-06-04), pages 103 - 112, XP002459838, ISSN: 0378-5173 *
MURA P ET AL: "TERNARY SYSTEMS OF NAPROXEN WITH HYDROXYPROPYL-BETA-CYCLODEXTRIN AND AMINOACIDS", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 260, no. 2, 24 July 2003 (2003-07-24), pages 293 - 302, XP008062550, ISSN: 0378-5173 *
REDENTI ENRICO ET AL: "Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 90, no. 8, August 2001 (2001-08-01), pages 979 - 986, XP002459837, ISSN: 0022-3549 *

Also Published As

Publication number Publication date
JP2010522730A (ja) 2010-07-08
WO2008135674A2 (fr) 2008-11-13
US20100087392A1 (en) 2010-04-08
CA2682250A1 (fr) 2008-11-13
EP2142187A2 (fr) 2010-01-13
FR2914187B1 (fr) 2011-01-21
FR2914187A1 (fr) 2008-10-03

Similar Documents

Publication Publication Date Title
WO2008135674A3 (fr) Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique
EP3406347A3 (fr) Compositions de conjugués xten et leurs procédés de fabrication
IL260158B (en) Pyrazine derivatives, preparations containing them and their uses
WO2006132670A3 (fr) Auristatines comportant une unite d'acide aminobenzoique au n-terminal
IL208937A0 (en) Cell binding agent cytotoxic drug conjugates, compositions comprising the same and uses thereof
WO2010040840A3 (fr) Particules de carbone revêtues avec des films de polymère, procédés pour leur production et utilisations de ceux-ci
WO2008138755A3 (fr) Compositions pharmaceutiques pour des médicaments solubles de façon médiocre
WO2010054154A3 (fr) Séquences crispr de bifidobactéries
WO2010008445A3 (fr) Compositions de pha ramifié, procédés pour leur production, et utilisation dans des applications
WO2010013224A3 (fr) Nanoparticules de curcumine et leurs procédés de production
IL204621A0 (en) Bicyclic - ?? - amino acid derivatives, compositions comprising the same and uses thereof
WO2009120893A3 (fr) Conjugués polypeptide-polymère et procédés d’utilisation de ceux-ci
WO2011146583A3 (fr) Formulations de cinacalcet nanoparticulaire
EP3626253A3 (fr) Formulations stables de linaclotide
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
WO2009032749A3 (fr) Peptides modifiés par des salicylanilides servant de substance thérapeutique orale
WO2009130602A3 (fr) Conjugués de facteur ix dotés de demi-vies prolongées
EP3381445A3 (fr) Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
WO2010035122A3 (fr) Complexe constitue d'un polysaccharide et d'une hpb
WO2009007535A3 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
WO2008154234A3 (fr) Formulation à libération prolongée de névirapine
IL210316A (en) History of Triazol Pharmacopoeias that contain them and their uses
WO2010116382A3 (fr) Compositions pharmaceutiques stables de diclofénac
WO2008073863A3 (fr) Préparation et utilité d'allylamines substituées
WO2007083190A8 (fr) Extrait d'helychrisum insoluble dans l'eau, et procédés d'élaboration et d'utilisation correspondants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08787859

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008787859

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010500319

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2682250

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE